Andrew Williams

Andrew is a senior finance & corporate executive with 20+ years of Executive Management experience in private & public companies. Currently the CFO of Pattern Pharma, he was also the COO/CFO of Cynapsus Therapeutics, a CNS company that developed a therapeutic for OFF episodes associated with Parkinson’s disease. In 2016, Cynapsus was acquired for $841 million by Sunovion Pharmaceuticals. While Andrew was CFO, Cynapsus raised approximately $170 million primarily via private placements & public offerings, including a $72.5 million US IPO & NASDAQ listing in June 2015.